See the DrugPatentWatch profile for zimhi
Why is coverage a concern?
Medicare coverage decisions can be complex, involving various factors such as patient eligibility, medication approval, and cost-sharing arrangements.
What is Zimhi?
Zimhi is a fentanyl transmucosal solution approved by the FDA under the 505(b)(2) pathway, intended for the treatment of acute breakthrough pain in adult patients with cancer[1]. It's essential to note that Zimhi has a unique formulation and administration method, which may impact its coverage decisions.
Does Medicare cover Zimhi?
According to the Zimhi FDA label, the manufacturer, Zefon International, LLC, did not initiate a Medicare Part D coverage decision[1][2]. As a result, the Centers for Medicare and Medicaid Services (CMS) has not established a national coverage determination (NCD) for Zimhi.
However, as a Medicare Part D medication, Zimhi will be covered under the Medicare Part D program, but coverage decisions may vary among Medicare Advantage (MA) and Part D plans[3].
Why is patient eligibility a factor?
Medicare coverage decisions are usually based on a patient's medical diagnosis and individual circumstances. In this case, patients with acute breakthrough pain due to cancer will require a prescription from a licensed healthcare provider. Coverage decisions will depend on various factors, including the patient's medical history, condition, and eligibility for Medicare.
How do Part D plans determine coverage?
Medicare Part D plans, including Medicare Advantage plans, will make coverage decisions based on factors such as drug formulary, patient eligibility, cost-sharing arrangements, and coverage limits. If Zimhi is on a plan's formulary, patients may have access to coverage, but copayment and coinsurance costs may apply.
What's the role of patient advocacy?
Patients and/or their caregivers should discuss Zimhi coverage with their healthcare provider, pharmacist, or Medicare representative to ensure they understand their individual coverage options and any requirements for coverage.
Sources:
[1] FDA: NDA 213-044: Zimhi (fentanyl) Transmucosal Solution (2021)
[2] DrugPatentWatch.com: Zimhi (fentanyl) Transmucosal Solution 2023
[3] Medicare.gov: Medicare Part D Coverage